外源GalR2特异性激剂作为治疗心肌缺血/再输伤的工具
Larisa Serebryakova1, Oksana Veselova1, Irina Studneva1
1Chazov National Medical Research Center of Cardiology, Moscow, Russia.
Fundamental & clinical pharmacology
|May 30, 2023
概括
激活GalR2受体可以保护老鼠的心脏免受缺血/再输血损伤. 加拉宁和一种激动剂 (G1) 显著减少了心脏损伤和心脏酶释放,这表明在缺血性心脏病中具有潜在的治疗应用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 缺血/反 (I/R) 损伤是导致心脏损伤的主要原因.
- 氨酸受体2 (GalR2) 是心脏保护的潜在目标.
- 了解GalR2在I/R损伤中的特定作用对于开发新疗法至关重要.
研究的目的:
- 研究GalR2激活在保护大鼠心脏免受I/R损伤中的作用.
- 为了评估加拉林胺激动剂 (G1) 和全长的加拉林 (G2) 在肌肉心脏I/R的老鼠模型中的疗效.
- 通过选择性抑制剂 (M871) 确定保护作用是否通过GalR2受体进行介导.
主要方法:
- 使用固相合成和HPLC进行类合成和净化.
- 在老鼠中通过LAD冠状动脉封闭和再注血诱导心肌内心I/R损伤.
- 评估心脏病发作大小 (IS) 和血肌酸酶-MB (CK-MB) 活性作为心脏损伤的标志物.
主要成果:
- 与对照组相比,静脉注射G1或G2显著降低了IS和CK-MB活性.
- 选择性GalR2抑制剂M871取消了G1的保护作用,表明GalR2的中介作用.
- M871减弱了G2的保护作用,但没有达到统计学意义.
结论:
- GalR2是主要的受体,它调解了加拉林和G1对I/R损伤的心脏保护作用.
- 特定于GalR2的激动剂显示出作为治疗缺血性心脏病的候选药物的前景.
- 准GalR2为心肌I/R损伤提供了一个潜在的治疗策略.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...